HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. (Q50761028)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 November 2013

Language	Label	Description	Also known as
English	HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.	scientific article published on 8 November 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Miao-Zhen Qiu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Qian Li

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Zhi-Qiang Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Tian-Shu Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Qing Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Xiao-Li Wei

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ying Jin

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

De-Shen Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Chao Ren

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Long Bai

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dong-Sheng Zhang

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Feng-Hua Wang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Yu-Hong Li

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

0 references

publication date

8 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

134

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2468-2477

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24155030%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Advanced HER2-positive gastric cancer: current and future targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28559

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50761028&oldid=1561187114"